Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bosly

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Acta Clinica Belgica|January 1, 1992
Large granular lymphocyte proliferative disease: 21 Belgian cases and review of the literatureP G Pierre, A Bosly, R De Bock, et al.
European Journal of Haematology|April 1, 1996
Infectious complications after 2-chlorodeoxyadenosine therapyE Van Den Neste, A Delannoy, B Vandercam, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphomaA Bosly, E Lepage, B Coiffier, et al.
The American Journal of Surgical Pathology|February 27, 2001
Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA studyD Cazals-Hatem, M André, N Mounier, et al.
Blood|June 25, 1998
Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)C Gisselbrecht, P Gaulard, E Lepage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'AdulteC Haioun, E Lepage, C Gisselbrecht, et al.
Cancer Genetics and Cytogenetics|November 1, 1996
Cytogenetic and clinicobiological features of acute leukemia with stem cell phenotype: study of nine casesA Cuneo, A Ferrant, J L Michaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte studyC Haioun, E Lepage, C Gisselbrecht, et al.
Leukemia & Lymphoma|April 1, 1997
Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'AdulteC Gisselbrecht, C Haioun, E Lepage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 17, 2009
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)H Ghesquières, C Ferlay, C Sebban, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Acta Clinica Belgica|January 1, 1992
Large granular lymphocyte proliferative disease: 21 Belgian cases and review of the literatureP G Pierre, A Bosly, R De Bock, et al.
European Journal of Haematology|April 1, 1996
Infectious complications after 2-chlorodeoxyadenosine therapyE Van Den Neste, A Delannoy, B Vandercam, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphomaA Bosly, E Lepage, B Coiffier, et al.
The American Journal of Surgical Pathology|February 27, 2001
Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA studyD Cazals-Hatem, M André, N Mounier, et al.
Blood|June 25, 1998
Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)C Gisselbrecht, P Gaulard, E Lepage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'AdulteC Haioun, E Lepage, C Gisselbrecht, et al.
Cancer Genetics and Cytogenetics|November 1, 1996
Cytogenetic and clinicobiological features of acute leukemia with stem cell phenotype: study of nine casesA Cuneo, A Ferrant, J L Michaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte studyC Haioun, E Lepage, C Gisselbrecht, et al.
Leukemia & Lymphoma|April 1, 1997
Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'AdulteC Gisselbrecht, C Haioun, E Lepage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 17, 2009
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)H Ghesquières, C Ferlay, C Sebban, et al.
Pageof 12